Paul Hastings LLP advised the lead placement agent and the placement agent. Skye Bioscience, Inc. (OTCQB: SKYE), a clinical stage biotechnology company focused on the discovery,...
Skye Bioscience’s $50.25 Million Private Placement
Biovian’s Partnership with 3P Biopharmaceuticals
Paul Hastings (Europe) LLP, Strelia, Garrigues and Castrén & Snellman advised Keensight Capital on the matter. Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development...